Regorafenib (BAY 73-4506)

製品コードS1178 別名:Fluoro-Sorafenib

Regorafenib (BAY 73-4506)化学構造

分子量(MW):482.82

Regorafenib (BAY 73-4506)は一種の多ターゲット阻害剤で、無細胞試験でVEGFR1、VEGFR2、VEGFR3、PDGFR-β、Kit、RETとRaf-1に作用する時のIC50値が13 nM、4.2 nM、46 nM、22 nM、7 nM、1.5 nMと2.5 nMにそれぞれ分かれることです。

サイズ 価格 在庫  
USD 211 あり
USD 151 あり
USD 264 あり
USD 592 あり
USD 1222 あり

製品安全説明書

VEGFR阻害剤の選択性比較

生物活性

製品説明 Regorafenib (BAY 73-4506)は一種の多ターゲット阻害剤で、無細胞試験でVEGFR1、VEGFR2、VEGFR3、PDGFR-β、Kit、RETとRaf-1に作用する時のIC50値が13 nM、4.2 nM、46 nM、22 nM、7 nM、1.5 nMと2.5 nMにそれぞれ分かれることです。
靶点
RET [1]
(Cell-free assay)
Raf-1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
Kit [1]
(Cell-free assay)
VEGFR1 [1]
(Cell-free assay)
1.5 nM 2.5 nM 4.2 nM 7 nM 13 nM
In vitro試験

Regorafenib strongly prevents VEGFR2 autophosphorylation in NIH-3T3/VEGFR2 cells with IC50 of 3 nM. In HAoSMCs, regorafenib suppress PDGFR-β autophosphorylation after stimulation with PDGF-BB, with an IC50 of 90 nM. Regorafenib also inhibits FGFR signaling in MCF-7 breast cancer (BC) cells stimulated with FGF10. Regorafenib very potently inhibited the mutant receptors KITK642E and RETC634W, with IC50 of approximately 20 nM and 10 nM, respectively. Regorafenib inhibits the proliferation of VEGF165-stimulated HUVECs, with an IC50 of approximately 3 nM. Regorafenib prevents the proliferation of FGF2-stimulated HUVECs and of PDGF-BB-stimulated HAoSMCs with IC50 of 127 nM and 146 nM, respectively. [1] Regorafenib targets both tumor cell proliferation and tumor vasculature through inhibition of receptors of tyrosine kinases (VEGFR, KIT, RET, FGFR, and PDGFR) and serine/threonine kinases (Raf and p38MAPK). [2] Regorafenib suppresses growth of human Hep3B, PLC/PRF/5 and HepG2 cells in a concentration- and time-dependent manner. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Hep3B M2WwcGFxd3C2b4Ppd{BCe3OjeR?= M{DhR|HjiJN3wrFOwG0> MX60PEBp NWrINHhWcW6qaXLpeJMh[2WubDDndo94fGh? M4izOVI3OzJ7NkC4
PLC/PRF/5  NHHE[|hCeG:ydH;zbZMhSXO|YYm= NFS2Wm0y6oDVNdMg{txO M4HIUVQ5KGh? MY\pcohq[mm2czDj[YxtKGe{b4f0bC=> MXWyOlMzQTZyOB?=
HepG2  MXHBdI9xfG:|aYOgRZN{[Xl? MXmx5qCUPcLizszN NVzEXotHPDhiaB?= MVfpcohq[mm2czDj[YxtKGe{b4f0bC=> MVKyOlMzQTZyOB?=
HEK293 M{PifGZ2dmO2aX;uJGF{e2G7 MX6wMlXjiIoQvF2= MnLtNk81NzZiaB?= NVq1ZWFVemWmdXPld{BIWlB5ODDlfJBz\XO|aX;u MmX3NlU5PThyM{K=
GEO NHnadXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TBSFAvODFvMkCg{txO MoHYPVYhcA>? MoTvSG1UVw>? MWrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MlrqNlU5Ozh|OUG=
SW48 NX\JNXBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Pa[lAvODFvMkCg{txO NU\SS41YQTZiaB?= MVLEUXNQ MoPTbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MV2yOVg{QDN7MR?=
HT29 MlPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHexNZkxNjBzLUKwJO69VQ>? NI\hOXQ6PiCq MnXoSG1UVw>? NFnMZ|hqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M{\rblI2QDN6M{mx
SW480 MmTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYOwMlAyNTJyIN88US=> NXP5T4VXQTZiaB?= MYfEUXNQ NXi3OZhDcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M2rHeFI2QDN6M{mx
SW620 MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWWwMlAyNTJyIN88US=> M3n6dVk3KGh? M2[5SGROW09? M1zzdIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MnvSNlU5Ozh|OUG=
HCT116 M1\kXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUW5c3l{OC5yMT2yNEDPxE1? MnnwPVYhcA>? M4K3bmROW09? M1PMSolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NEHvV2wzPTh|OEO5NS=>
LOVO M3LyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\DSpcxNjBzLUKwJO69VQ>? M4GydFk3KGh? NV\RSINzTE2VTx?= MmDabY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NUDDU4tQOjV6M{izPVE>
HCT150 MnWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHINE4xOS1{MDFOwG0> MlTHPVYhcA>? NYPFdIxETE2VTx?= MoTvbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M3PubFI2QDN6M{mx
SW48-CR NEewfGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mon2NE4xOS1{MDFOwG0> M1rKXlk3KGh? NWrsO|NzTE2VTx?= NFrp[WlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MkLtNlU5Ozh|OUG=
GEO-CR MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3GwflAvODFvMkCg{txO M4DRe|k3KGh? NUXHb5lzTE2VTx?= NILaO4RqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NHSycFkzPTh|OEO5NS=>
KB-31 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTVwNdMxNE4{KG6P MYCyOVc2OzN4MR?=
KB-G2 M4TMZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFL3eHhKSzVyPUmuNeKyOC5zIH7N MVeyOVc2OzN4MR?=
LLC-PK1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHzbFhKSzVyPUSyMlDDuTNwMjDuUS=> MV[yOVc2OzN4MR?=
LLC-PK1/MRP2 NEH2eGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnXTWM2OD16Mj60xtEzNjdibl2= NFTFfWozPTd3M{O2NS=>
HEK293 NUPsW|dFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTFzLkFCtVEvOiCwTR?= NWHzUZI1OjV5NUOzOlE>
HEK293/OATP1B1 NFK5b2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HGRWlEPTB;Nj6yxtExNjNibl2= NIrvSowzPTd3M{O2NS=>
HROC18 M4LRUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTFwMzFOwG0> MUCyOVMxQTlzNB?=
HROC24 M1XQUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrNTWM2OD12Lk[g{txO MlLUNlU{ODl7MUS=
HROC43 MonlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{e2dGlEPTB;NT6zJO69VQ>? NWroSXZZOjV|MEm5NVQ>
HROC46 NFLEV5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorCTWM2OD1{LkSg{txO NEHUU3EzPTNyOUmxOC=>
RJ345 M2DjVGZ2dmO2aX;uJGF{e2G7 M4DkWFAvPS93IN88US=> NV\Td4lCOjRiaB?= MVPEUXNQ MnjzbY5pcWKrdIOgeIhmKGOnbHygcYloemG2aX;u Ml7DNlUzPTN7OUS=
RJ348 NHvwdohHfW6ldHnvckBCe3OjeR?= NFrnU|ExNjVxNTFOwG0> NEf3Z5EzPCCq Mn2wSG1UVw>? NIPn[IFqdmirYnn0d{B1cGViY3XscEBucWe{YYTpc44> NFriWnAzPTJ3M{m5OC=>
MCF-7 NFyyZ5RHfW6ldHnvckBCe3OjeR?= NXW0OIgzOC53L{Wg{txO M1HoW|I1KGh? NYTNVGpVTE2VTx?= NXXrO4lzcW6qaXLpeJMhfGinIHPlcIwhdWmpcnH0bY9v M1jndFI2OjV|OUm0
MDA-MB-231 MX7GeY5kfGmxbjDBd5NigQ>? NX\TTFdROC53L{Wg{txO MorhNlQhcA>? MnLMSG1UVw>? NIDWe3NqdmirYnn0d{B1cGViY3XscEBucWe{YYTpc44> NILqdlkzPTJ3M{m5OC=>
HT15 NHvsZZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnQRlBvOS1{MDFOwG0> NVniXo8{PDhiaB?= NHPMOVJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MVKyOVA4OTBzOB?=
DLD1 M3rJb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjQNU0zOCEQvF2= MWW0PEBp M4Pxb4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MVGyOVA4OTBzOB?=
HT-29 MoPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWr2O4NXOS1{MDFOwG0> M135ZVQ5KGh? NEDRXXJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MnrRNlUxPzFyMUi=
Hct-116 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV2xMVIxKM7:TR?= MXm0PEBp NYPxboF3cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NXn5SI9IOjVyN{GwNVg>
HT15 M1LsV2Fxd3C2b4Ppd{BCe3OjeR?= NFT6W24yNTFyIN88US=> MoTFOFghcA>? NG\tZlhqdmS3Y3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MYSyOVA4OTBzOB?=
DLD1 M33hU2Fxd3C2b4Ppd{BCe3OjeR?= MnjrNU0yOCEQvF2= MXi0PEBp NX\jbnZjcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NEnxdGYzPTB5MUCxPC=>
HT-29 NGruUnNCeG:ydH;zbZMhSXO|YYm= NVLGcHBlOS1zMDFOwG0> MYK0PEBp NWfUN4FvcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MlfNNlUxPzFyMUi=
Hct-116 NFrEeJRCeG:ydH;zbZMhSXO|YYm= MnnQNU0yOCEQvF2= MXm0PEBp MoDtbY5lfWOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M1LVOlI2ODdzMEG4
GBM5 M2GwbGFxd3C2b4Ppd{BCe3OjeR?= NHfTb4kxNjYkgKOxMlDjiIoQvF2= NEDyVJczPCCq M4[zTGROW09? MYrpcpRmemGldIOge4l1cCCuYYDheIlvcWJidH:gbY5lfWOnIHPlcIwh\GWjdHi= MoXZNlQ6OTF{MUW=
GBM6 MXrBdI9xfG:|aYOgRZN{[Xl? MmDWNE426oDVMT6w5qCK|ryP NF3meoYzPCCq NFv3fXhFVVOR M4XOdYlvfGW{YXP0d{B4cXSqIHzhdIF1cW6rYjD0c{BqdmS3Y3WgZ4VtdCCmZXH0bC=> MWSyOFkyOTJzNR?=
GBM12 MnnVRZBweHSxc3nzJGF{e2G7 M4jPSlAvPeLCk{GuNQKBkc7:TR?= MlLLNlQhcA>? MoDKSG1UVw>? NI\NUYxqdnSncnHjeJMhf2m2aDDsZZBifGmwaXKgeI8hcW6mdXPlJINmdGxiZHXheIg> NF\1fowzPDlzMUKxOS=>
GBM14  M2jjd2Fxd3C2b4Ppd{BCe3OjeR?= MlvvNE426oDVMT6w5qCK|ryP MVyyOEBp MXrEUXNQ NYTEZWU{cW62ZYLhZ5R{KHerdHigcIFx[XSrbnniJJRwKGmwZIXj[UBk\WyuIHTlZZRp MYWyOFkyOTJzNR?=
Hep3B MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELUOIcy6oDVMj61xsDPxE1? M2HIflI1NzR6L{eyJIg> NGmx[JVqdmirYnn0d{Bk\WyuIHfyc5d1cA>? NIK3UGszPDh6NUi5NC=>
PLC/PRF/5  MlzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfa[VJOOeLCk{KuOeKh|ryP M2jjfFI1NzR6L{eyJIg> MnqxbY5pcWKrdIOgZ4VtdCCpcn;3eIg> NXHaVlhLOjR6OEW4PVA>
HepG2  Mn;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPwNgKBmzJwNdMg{txO MonKNlQwPDhxN{KgbC=> MV;pcohq[mm2czDj[YxtKGe{b4f0bC=> NYTOU484OjR6OEW4PVA>
HCT116  NGPKfHhHfW6ldHnvckBCe3OjeR?= MXOxNE8zOC92MDFOwG0> M1j0bFI1KGh? NXzOcoJJcW6mdXPld{BRXU2DIIDyc5RmcW5iYX7kJI1TVkFiZYjwdoV{e2mxbjDpckBiKGSxc3WtJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NFvTVJAzPDd4M{[xNS=>
Lim2405 MoftSpVv[3Srb36gRZN{[Xl? MWC0NEDPxE1? NWG4bJJ6OjRiaB?= M4jlfIlv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? NXvDUXJNOjR5NkO2NVE>
LoVo NXKzcHo4TnWwY4Tpc44hSXO|YYm= Ml7WOFAh|ryP NFjw[5MzPCCq NVmxU5h{cW6mdXPld{BRXU2DIIDyc5RmcW5iYX7kJINmdGxiYYDvdJRwe2m| M{PmPVI1PzZ|NkGx
Lim1215 M1PhfmZ2dmO2aX;uJGF{e2G7 M3H4c|QxKM7:TR?= MmnVNlQhcA>? MY\pcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> MV:yOFc3OzZzMR?=
SW48 NID3dmRHfW6ldHnvckBCe3OjeR?= NXvvOW5UPDBizszN M{DBS|I1KGh? NHPHRmlqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? MoPwNlQ4PjN4MUG=
RKO  MmrFSpVv[3Srb36gRZN{[Xl? NGHSfoY1OCEQvF2= Ml;ONlQhcA>? M1;KSolv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? NYjUU3JyOjR5NkO2NVE>
SW837 M17I[mZ2dmO2aX;uJGF{e2G7 MUS0NEDPxE1? MWSyOEBp NHTqOZZqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? MXSyOFc3OzZzMR?=
SW1463 NX;zdXlKTnWwY4Tpc44hSXO|YYm= NELieok1OCEQvF2= MYGyOEBp M1nNTolv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? M3;vPFI1PzZ|NkGx
SW480 MorTSpVv[3Srb36gRZN{[Xl? NFXjT441OCEQvF2= NWjLc3puOjRiaB?= MWjpcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> M17mRVI1PzZ|NkGx
Vaco432 MWLGeY5kfGmxbjDBd5NigQ>? M1;EUFQxKM7:TR?= MWqyOEBp M4PhU4lv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? MV:yOFc3OzZzMR?=
Vaco400 NG\1WmpHfW6ldHnvckBCe3OjeR?= NGLwcGM1OCEQvF2= M2LrOFI1KGh? MWHpcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> MXOyOFc3OzZzMR?=
DLD1 NWqxZlhUTnWwY4Tpc44hSXO|YYm= MYi0NEDPxE1? NVLJPVF4OjRiaB?= M2nseolv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? MXGyOFc3OzZzMR?=
HT29  MVzGeY5kfGmxbjDBd5NigQ>? MWm0NEDPxE1? Ml7xNlQhcA>? MXTpcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> MojhNlQ4PjN4MUG=
PLC/PRF/5  NWTtdY9QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknlNgKBmzYEtV2= NVHBdI43OjRxNEivO|IhcA>? M{PCVYlvcGmkaYTzJINmdGxiZ4Lve5Rp M{HG[VI{OTZ7MUS4
HepG2 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2[5OVHjiJN3wsXN NH;OUWIzPC92OD:3NkBp MkTMbY5pcWKrdIOgZ4VtdCCpcn;3eIg> MoTkNlMyPjlzNEi=
Hep3B  NWn2[oxIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTVUFFbOeLCk{ZCuW0> NXL1TZJzOjRxNEivO|IhcA>? MmfabY5pcWKrdIOgZ4VtdCCpcn;3eIg> NVHPbGFlOjNzNkmxOFg>

... Click to View More Cell Line Experimental Data

In vivo試験 Regorafenib reveals potent dose-dependent TGI in various preclinical human xenograft models in mice, with tumor shrinkages in breast MDA-MB-231 and renal 786-O carcinoma models. Regorafenib prevents not only the growth of syngeneic primary 4T1 breast tumors growing orthotopically in the fat pad, but also suppresses the formation of tumor metastasis in the lung. [1]

プロトコル(参考用のみ)

キナーゼアッセイ:[1]
+ 展開

Kinase assays:

In vitro assays using recombinant VEGFR2 (murine aa785–aa1367), VEGFR3 (murine aa818–aa1363), PDGFRβ (aa561–aa1106), Raf-1 (aa305–aa648) and BRafV600E (aa409–aa765) kinase domains are performed. Initial in vitro kinase inhibition profiling is performed at a fixed 1 μM Regorafenib concentration. Inhibitory concentration of 50% (IC50) values are determined from selected responding kinases, e.g., VEGFR1 and RET. TIE2 kinase inhibition is measured with a homogeneous time-resolved fluorescence (HTRF) assay using a recombinant fusion protein of glutathione-S-transferase, the intracellular domain of TIE2 and the peptide biotin-Ahx-EPKDDAYPLYSDFG as substrate.
細胞アッセイ: [1]
+ 展開
  • 細胞株: GIST 882 and TT cells
  • 濃度: 5 nM-10 μM
  • 反応時間: 96 hours
  • 実験の流れ: For proliferation assays, GIST 882 and TT cells are grown in RPMI medium containing L-glutamine, and MDA-MB-231, HepG2 and A375 cells in DMEM always containing 10% hiFBS. Cells are trypsinized, plated at 5×104 cells/well in 96-well plates in complete media containing 10% FBS and grown overnight at 37 °C. The next day, vehicle or Regorafenib serially diluted in complete growth media to between 10 μM and 5 nM final concentrations, and 0.2% DMSO, is added and incubation is continued for 96 hours. Cell proliferation is quantified.
    (参考用のみ)
動物実験:[1]
+ 展開
  • 動物モデル: Female athymic NCr nu/nu mice with Colo-205, MDA-MB-231 or 786-O
  • 製剤: PEG400/125 mM aqueous methanesulfonic acid (80/20) or polypropylene glycol/PEG400/Pluronic F68 (42.5/42.5/15 + 20% Aqua)
  • 投薬量: 3 mg/kg, 10 mg/kg, 30 mg/kg, 100 mg/kg
  • 投与方法: Orally
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 97 mg/mL (200.9 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
体内 30% PEG400+0.5% Tween80+5% propylene glycol 30 mg/mL

* <1 mg/mlは製品が微弱に溶解する或いは溶解しないことを示します。
* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 482.82
化学式

C21H15ClF4N4O3

CAS No. 755037-03-7
保管
in solvent
別名 Fluoro-Sorafenib

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02795156 Recruiting Non-small Cell Lung Carcinoma|Urothelial Carcinoma|Gastrointestinal Carcinoma, Non-colon|Upper Aerodigestive Tract Carcinoma SCRI Development Innovations, LLC|Foundation Medicine|Boehringer Ingelheim|Bayer September 28, 2016 Phase 2
NCT03042689 Not yet recruiting Acute Myeloid Leukemia Massachusetts General Hospital|Bayer January 2017 Phase 1
NCT02910843 Not yet recruiting Rectal Cancer Swiss Group for Clinical Cancer Research December 2016 Phase 1
NCT02940223 Not yet recruiting Malignant Neoplasms of Independent (Primary) Multiple Sites|Metastatic Colorectal Cancer M.D. Anderson Cancer Center|Bayer December 2016 Phase 2
NCT02955940 Enrolling by invitation Pancreatic Cancer|Colorectal Cancer|Breastcancer|Lung Cancer Non-Small Cell Incyte Corporation November 2016 Phase 2
NCT02889328 Recruiting Gastrointestinal Stromal Tumors (GISTs) Asan Medical Center September 2016 Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

VEGFR信号経路図

VEGFR Inhibitors with Unique Features

相関VEGFR製品

Tags: Regorafenib (BAY 73-4506)を買う | Regorafenib (BAY 73-4506) ic50 | Regorafenib (BAY 73-4506)供給者 | Regorafenib (BAY 73-4506)を購入する | Regorafenib (BAY 73-4506)費用 | Regorafenib (BAY 73-4506)生産者 | オーダーRegorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506)化学構造 | Regorafenib (BAY 73-4506)分子量 | Regorafenib (BAY 73-4506)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID